Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.

Pharmaceutical

Olatec Therapeutics

Olatec Therapeutics' headquarters in New York, NY, United States

Damaris B. Skouras

Sophia Hughes

Piscitelli Philip

Jeanette Rooney, CPA, CGMA

Cynthia (Dana) Barrow

Charles A. Dinarello

Robert H. Dworkin

Steven B. Newhard

Shayne C. Gad

Leo A. B. Joosten

Howard I. Maibach

Alberto Mantovani

F. Kip Vought

Timotheus Jansen

Jose Ángel Cordova Villalobos

Matthijs Janssen

Antonio Abbate

William J. Cunningham

Robert M. Fielding

Lucio C. Rovati

Gregory K. Palm

Craig T. Basson

Spyros S. Skouras, Jr.

Valentín Campos, Sr.

John F. Otto

George A. Skouras

Andrea Leonard-Segal

Peter Libby

Viola T. Kung

Marc J. Philippon

Amy K. Poshusta

Daniel Yadegar

The Scientific Advisors at Olatec Therapeutics are tasked with providing expert guidance on the design, development, and implementation of research projects related to NLRP3 antagonist therapeutics. They leverage their extensive knowledge in immunology and pharmacology to help shape clinical strategies, support regulatory submissions, and ensure that the scientific integrity of the company's therapeutic innovations is maintained. By collaborating with cross-functional teams, they aim to advance Olatec’s mission of addressing a wide range of inflammatory diseases.

Scientific Advisors

The Leadership Team at Olatec Therapeutics is responsible for guiding the company's strategic direction and overseeing the development of its proprietary NLRP3 antagonist therapeutics. This team, comprised of executives with expertise in medicine, finance, compliance, and clinical operations, ensures alignment between research initiatives and business objectives while fostering an environment of innovation to address complex inflammatory diseases. They play a critical role in decision-making, regulatory compliance, and the allocation of resources to advance Olatec’s mission.

Leadership Team

The Clinical Advisors team at Olatec Therapeutics provides expert guidance on the design and execution of clinical trials for the company's NLRP3 antagonist therapeutics. They collaborate with cross-functional teams to ensure that clinical strategies align with regulatory requirements and scientific goals, while also interpreting clinical data to inform the development of treatments for inflammatory diseases. Their insights help drive the advancement of innovative therapies from the lab to clinical practice.

Clinical Advisors

The Clinical Development team at Olatec Therapeutics is responsible for designing and implementing clinical trials to evaluate the safety and efficacy of the company's innovative NLRP3 antagonist therapeutics. This team collaborates closely with cross-functional partners to ensure compliance with regulatory standards, optimize trial designs, and analyze clinical data, ultimately advancing the development of therapies for a range of inflammatory diseases. Their efforts are essential for bringing new treatment options to patients and supporting the company's mission of addressing unmet medical needs.


Clinical Development

Olatec Therapeutics

Org chart

Board & advisors

Teams

Scientific Advisors

Leadership Team

Clinical Advisors

Clinical Development

Offices

Olatec Therapeutics

Org chart

Board & advisors

Teams

Scientific Advisors

Leadership Team

Clinical Advisors

Clinical Development

Offices

Related companies